SCHEMBL31661819

SCHEMBL31661819

O=C(O)CCCCc1cccc(NC(=O)c2ccccc2O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.64
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
HPGD P15428 2/20 0.56
HTT P42858 2/20 0.56
HSD17B10 Q99714 2/20 0.56
KDM4E B2RXH2 2/20 0.56
LMNA P02545 1/20 0.56
TP53 P04637 1/20 0.56
P2RX1 P51575 2/20 0.54
FADS1 O60427 1/20 0.54
TERT O14746 1/20 0.52
PPARG P37231 2/20 0.52
PPARA Q07869 2/20 0.52
NR1H4 Q96RI1 2/20 0.52
PPARD Q03181 1/20 0.52
MAPT P10636 2/20 0.51
NPC1 O15118 2/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5668315 1.00 ALOX15 (0.64) ALOX15MEN1KMT2AHPGDHTT
SCHEMBL5718041 0.91 ALOX15 (0.72) ALOX15MEN1KMT2AHPGDHTT
SCHEMBL5656623 0.86 ALOX15 (0.72) ALOX15MEN1KMT2AHPGDHTT
SCHEMBL13593264 0.85 ALOX15 (0.70) ALOX15MEN1KMT2AHPGDHTT
SCHEMBL13593288 0.82 F2R (0.57) MEN1KMT2APPARGPPARANR1H4
SCHEMBL13593293 0.82 MEN1 (0.58) ALOX15MEN1KMT2APPARGPPARA
SCHEMBL6381563 0.82 ALOX15 (0.70) ALOX15MEN1KMT2AHPGDHTT
SCHEMBL10973331 0.80 ITGB3 (0.64) MEN1KMT2AHPGDPPARGPPARA
SCHEMBL5106598 0.79 MEN1 (0.65) MEN1KMT2AHSD17B10MAPTNPC1
SCHEMBL4956456 0.78 EPHX2 (0.58) MEN1KMT2AHPGDHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION LE ROUX DANIELLE MARIE (US) 2026-03-19 US disclosed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION VIP, GIPR, SLC10A2 ALOX15 1799/4885MEN1 1001/4885KMT2A 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.